TJP1 protein may identify multiple myeloma patients most likely to benefit from proteasome inhibitors
Thursday, April 28, 2016 - 14:40
in Health & Medicine
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study.